Skip to content

Innoviva, Inc. INVA Total Equity

Total Equity at other companies

Pfizer logo
PfizerPFE
$90.1B-0.3%
Merck & Co. logo
Merck & Co.MRK
$45.88B-5.1%
AbbVie logo
AbbVieABBV
-$6.66B-569%
Insmed logo
InsmedINSM
$704.85M+611%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$491.41M+3.3%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$323.98M+60.0%

Other financials

Income statement

See full
Revenue$98.0M+10.6%
Gross profit$75.8M+3.4%
Operating income$38.2M-7.9%
Net income$186.6M+501%
EPS (diluted)$2.22+400%

Balance sheet

See full
Cash & equivalents$603.1M+89.0%
Total debt$269.4M-40.3%
Total assets$1.8B+46.4%

Cash flow

See full
Operating cash flow$35.3M-27.4%
CapEx$492.0K
Free cash flow$34.8M-28.4%

Valuation

See full
Market cap$1.74B+51.8%
Enterprise value$1.4B+9.7%
P/E3.5×
P/S4.1×+1.0×

Profitability

See full
Gross margin73.7%-9.9pp
Operating margin38.1%-11.2pp
Net margin119.9%+107pp
FCF margin54.1%+5.3pp

Returns & leverage

See full
Return on equity29.1%
Debt / equity0.2×
Current ratio21.1×+18.7×

Where this comes from

Reported directly by Innoviva, Inc. in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Innoviva, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Innoviva, Inc.'s total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Innoviva, Inc.'s total equity?
Innoviva, Inc. (INVA) reported total equity of $1.34B in Q1 2026.
What is the long-term trend for Innoviva, Inc.'s total equity?
Over 4 years (2020 to 2025), Innoviva, Inc.'s total equity has grown at a 21.4% compound annual growth rate (CAGR), from $539.91M to $1.17B.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.